ABSTRACT
Background: Simulation-based learning (SBL) enhances problem-solving, improves skills in health care professionals. Authors assessed its use in teaching and learning pharmacology among medical undergraduates exposed to METIman, human patient simulator.Methods: Medical undergraduate students exposed to SBL for over a year (8 clinical pharmacology related scenarios) were asked to fill a validated questionnaire at the end of the academic year.Results: Of 145 students who underwent SBL, the data of 84 were analysed. The overall satisfaction score with SBL was highly significant in 79 (94%) with a score of 26-35. Participants opined that it increases the depth of experience (91.6%), provides a no risk learning and immediate feedback opportunity (93.4%), a good opportunity to come across rare scenarios (86.2%), enhances decision making, communication, teamwork and skill development (92%); opportunity of repeated learning and enhanced patient safety at hospitals (89.28%), reduces the dependency on patients (72.8%), good opportunity for crisis training (88.0%) were other factors favouring the use of SBL. Preference for an increase in the number of classes allotted to simulation (27.4%) and reducing the duration of class (9.6%) were the major suggestions. It is an excellent method to teach and make it interesting to learn pharmacology (80.0%)Total score varied between 23-35 with a mean盨D of 35�.64. None had a score of 7-15.Conclusions: SBL is an effective teaching and learning methodology with adequate participant satisfaction. It can be of immense utility as a learning tool with better outcome in learning, retention and recall.
ABSTRACT
Canine parvovirus (CPV) is an emerged pathogen in dogs, first isolated in 1978 in the USA. The original 1978 strain was designated CPV type 2 (CPV-2). However, analysis of CPV isolates in the USA by restriction enzymes and monoclonal antibodies have shown that around the year 1979 a CPV variant strain, designated CPV type 2a (CPV-2a), became widespread. Subsequently, a new antigenic strain, designated CPV type 2b (CPV-2b), was also observed by analysis of CPV isolates from various parts of the world, although the proportion of each strains was different between countries. In this study, the Haemagglutination Inhibition (HI) test with a panel of monoclonal antibodies was used to type canine parvovirus strains in 29 fecal samples collected from symptomatic dogs from 1980 to 1986 and from 1990 to 1995. The results showed a strong predominance of the antigenic type 2a indicating that the CPV epizooty in Brazil followed the same pattern observed in European and Asian countries.
O Parvovírus Canino (CPV) é um patógeno emergente em cães, isolado pela primeira vez em 1978, nos Estados Unidos. A amostra original de 1978 foi designada CPV tipo 2 (CPV-2). Entretanto, análises de isolados de CPV dos Estados Unidos, por enzimas de restrição e anticorpos monoclonais demonstraram que cerca de 1979, uma amostra variante, designada CPV tipo 2a (CPV-2a) tornou-se prevalente. Subseqüentemente, uma nova amostra antigênica, designada CPV tipo 2b (CPV-2b) também foi observada por análises de isolados de CPV de várias partes do mundo, embora a proporção fosse diferente entre os países. Nesse estudo, foi utilizado o teste de Inibição da Hemaglutinação (HI) com um painel de anticorpos monoclonais para a tipagem de 29 amostras fecais de parvovirus canino, coletadas de cães sintomáticos de 1980 a 1986 e de 1990 a 1995. Os resultados indicaram uma forte predominância do tipo antigênico 2a indicando que a epizootia de CPV no Brasil seguiu o mesmo padrão observados na Europa e países Asiáticos.